Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1964 • ACR Convergence 2022
Systematic Screening of Multimorbidities Results in an Increased Intake of Comorbidity Preventive Medications and a Decreased Hospitalization Rate
Claire DAIEN¹, Vera Georgescu², Guillaume Decarriere³, Jenica Pastor³, Gaël Mouterde⁴, Cédric Lukas⁵, Grégoire Mercier³ and Jacques Morel⁶, ¹University Hospital, Saint-Gély-du-Fesc, France, ²Unité de Recherche Médico-économique, CHU de Montpellier et Université de Montpellier, Montpellier, France, ³CHU Montpellier, Montpellier, France, ⁴Lapeyronie Hospital, Montpellier, France, ⁵University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, ⁶University and CHU Montpellier, Montpellier, France
Background/Purpose: A systematic screening of multimorbidities is performed since 2014 at the Montpellier University Hospital in patients with chronic inflammatory rheumatic diseases (IRD). The objective…
Abstract Number: 1982 • ACR Convergence 2022
Pluripotency Marker PBX1 Predicts Treatment Effect in Rheumatoid Arthritis
Karin Andersson¹, Eric Malmhäll-Bah², Nina Oparina¹, Tao Weiyang³, Malin Erlandsson¹, Venkataragavan Chandrasekaran², Aridaman Pandit³, Sofia Töyrä Silfverswärd⁴, Maria Bokarewa⁴ and Rille pullerits⁴, ¹Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³Center for Translational Immunology, University Medical Center, Utrecht, Netherlands, ⁴Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Background/Purpose: Self-renewal ability, which is important for the adaptive immunity and adequate T cell function, is severely impaired in rheumatoid arthritis (RA). This leads to…
Abstract Number: 1999 • ACR Convergence 2022
Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)
Vibeke Strand¹, Emelly Rusli², Lixia Zhang², Christina Le-Short², Alix Arnaud², Johanna Withers³ and Sam Asgarian², ¹Stanford University School of Medicine, Stanford, CA, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corportaion, Waltham, MA
Background/Purpose: Rheumatoid arthritis (RA) treatment response is typically defined using clinician-reported scores and patient global assessments of disease activity (PtGA), but patients may have a…
Abstract Number: 2015 • ACR Convergence 2022
JAK Selectivity Did Not Affect to the Incidence of Malignancies in the Real-World Setting: Data from a Multicenter Observational Study in Japan
Tomohisa Uchida¹, Naoki Iwamoto², Shoichi Fukui², Fumiko Shomura³, Koichiro Aratake³, Toshiyuki Aramaki⁴, Yukitaka Ueki⁴ and Atsushi Kawakami², ¹Department of Rheumatology, National Hospital Organization Ureshino Medical Center, Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Ureshino, Japan, ²Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, ³Department of Rheumatology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan, ⁴Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan

Background/Purpose: Tofacitinib and baricitinib are the first and second approved JAK inhibitors for rheumatoid arthritis (RA) patients. Although their clinical efficacy has been well established,…
Abstract Number: 2218 • ACR Convergence 2022
Frailty Is Associated with Serious Infections in Biologic and Targeted-synthetic DMARD Treated Patients with Rheumatoid Arthritis
Namrata Singh¹, Laura Gold², Katherine Wysham³, James Andrews², Pankti Reid⁴, Una Makris⁵, Bryant England⁶, Jiha Lee⁷, Michael George⁸, Joshua Baker⁹, Jeffrey Jarvik², Patrick Heagerty² and Siddharth Singh¹⁰, ¹University of Washington, Bellevue, WA, ²University of Washington, Seattle, WA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴University of Chicago Medical Center, Chicago, IL, ⁵UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Pennsylvania, Philadelphia, PA, ⁹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ¹⁰University of California San Diego, San Diego
Background/Purpose: Recently, it has been recognized that frailty and pre-frailty are common in patients with rheumatoid arthritis (RA) [1]. Whether frailty status portends an increased…
Abstract Number: PP18 • ACR Convergence 2022
From Devastated to Empowered: How Patient Engagement in Research Changes Lives
Eileen Davidson, Burnaby, BC, Canada
Background/Purpose: In April of 2015 I was a 29 year-old single mom diagnosed with rheumatoid arthritis (RA). RA wasn't unknown to me; my aunt who…
Abstract Number: 0024 • ACR Convergence 2021
Heterogeneity of Inflammatory HLA-DR+ Synovial Fibroblasts in Rheumatoid Arthritis Is Driven by Responses to Leukocyte-Derived Cytokines
Melanie Smith¹, Alejandro Kochen¹, Vianne Gao², Michail Schizas², Edward DiCarlo¹, Susan Goodman¹, Christina Leslie³, Laura Donlin¹ and Alexander Rudensky⁴, ¹Hospital for Special Surgery, New York, NY, ²Memorial Sloan Kettering Cancer Center, New York, NY, ³Computational and Systems Biology Program Memorial Sloan Kettering Cancer Center, New York, NY, ⁴Memorial Sloan Kettering Cancer Center / Howard Hughes Medical Institute, New York, NY
Background/Purpose: Treatment-refractory rheumatoid arthritis (RA) represents a major unmet need with substantial societal burden. Targeting RA-associated fibroblast-like synoviocytes (FLS) may provide a less-immunosuppressive therapeutic option.…
Abstract Number: 0040 • ACR Convergence 2021
M1-M2 Polarization by CTLA4-Ig (Abatacept) on Cultured Circulating Monocytes from Rheumatoid Arthritis Patients and Healthy Subjects
Samuele tardito¹, Stefano Soldano², Emanuele Gotelli², Paola Montagna¹, Rosanna Campitiello², Sabrina Paolino², Carmen Pizzorni¹, Alberto Sulli², Vanessa Smith³ and Maurizio Cutolo², ¹Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Dept. Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ³Department of Rheumatology and Internal Medicine, Ghent University Hospital, Ghent, Belgium
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disorder affecting 1% of the population worldwide [1]. Monocytes/macrophages are known to play a crucial role in…
Abstract Number: 0137 • ACR Convergence 2021
Antiviral Use and Healthcare Resource Utilization Among Patients with Rheumatoid Arthritis and Influenza in Three Influenza Seasons, 2016–2019
Edward Neuberger¹, Tu My To¹, Arpamas Seetasith¹, Stella Arndorfer² and Christopher Wallick¹, ¹Genentech, Inc., South San Francisco, CA, ²Genesis Research, South San Francisco, CA
Background/Purpose: Seasonal influenza poses a large burden on the healthcare system. Patients with certain chronic diseases, such as rheumatoid arthritis (RA), are especially vulnerable to…
Abstract Number: 0227 • ACR Convergence 2021
Work Participation Is Impaired Months Before Clinical Arthritis Is Apparent
Cleo Rogier¹, Pascal de Jong², Annette H.M van der Helm-van Mil³ and Elise van Mulligen⁴, ¹Erasmus MC, Rotterdam, ²Erasmus MC, Hendrik Ido Ambacht, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Work participation is still a major issue for patients with rheumatoid arthritis (RA) despite improved management and outcomes. Work loss can be divided into…
Abstract Number: 0279 • ACR Convergence 2021
Macrophage Cholesterol Loading Associates with Low-density Lipoprotein Structure, Oxidation, Antibodies Against Oxidized Epitopes and Is Modified by Immunomodulatory Treatments in Patients with Rheumatoid Arthritis
George Karpouzas¹, Bianca Papotti², sarah ormseth³, Marcella Palumbo⁴, Elizabeth Hernandez³, Cinzia Marchi⁴, Francesca Zimetti⁴, Franco Bernini⁴ and Nicoletta Ronda⁴, ¹Harbor-UCLA Medical Center, Torrance, CA, ²2. Department of Food and Drug, University of Parma, Italy, Parma, Italy, ³The Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, ⁴Department of Food and Drug, University of Parma, Parma, Italy
Background/Purpose: In Rheumatoid arthritis (RA), immune dysregulation, excess inflammation and oxidative stress may alter lipoprotein level and function and promote LDL oxidation and its uptake…
Abstract Number: 0354 • ACR Convergence 2021
A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Systemic Lupus Erythematosus
Kathryn Starzyk¹, Gary Curhan² and Julia Brault², ¹OM1, Inc, Boston, MA, ²OM1, Boston, MA
Background/Purpose: Features of autoimmune conditions may coexist in individual patients, which may represent an overlapping single disease with features of both (i.e., ‘rhupus’), or the…
Abstract Number: 0527 • ACR Convergence 2021
Role of Terminal Uridylyl Transferase 7 in TNF-α-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts In Vitro
Anil singh, farheen Shaikh and Salah-uddin Ahmed, Washington State University, Spokane, WA
Background/Purpose: Terminal uridylyl transferase 7 (TUT7), also known as Zcchc6, is a zinc finger domain-containing protein responsible for terminal uridylation of miRNA, implicated in pre-miRNA…
Abstract Number: 0581 • ACR Convergence 2021
Rheumatoid Arthritis Treatment Patterns in Massachusetts: Informative Findings from Insurance Claims Data
Mark Matza¹, D. Steven Fox², Kay Larholt³, David Fritsche³, Elizabeth Apgar³, Mitesh Puthran³, Gigi Hirsch³ and Marcy Bolster¹, ¹Massachusetts General Hospital, Boston, MA, ²University of Southern California, School of Pharmacy, Los Angeles, CA, ³Massachusetts Institute of Technology (MIT) Center for Biomedical Innovation, Cambridge, MA
Background/Purpose: A real-world current state of RA patients in Massachusetts (MA) is analyzed to provide a novel assessment of demographics, treatment patterns, and clinical settings…
Abstract Number: 0609 • ACR Convergence 2021
Challenges of Caring for Patients with Inflammatory Arthritis Experiencing Homelessness: Preliminary (12- Month) Follow-up Observations and Identification of Certain Barriers to Care
Baljeet Rai¹, Nicole Zagelbaum Ward², Abhimanyu Amarnani², Corinne Feldman², Brett Feldman² and Richard Panush², ¹LAC+USC Medical Center, Modesto, CA, ²LAC+USC Medical Center, Los Angeles, CA
Background/Purpose: Homelessness is a public health crisis. Those with housing insecurity have unique barriers to healthcare that confound their outcomes. Because of the paucity of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].